Lunit

Lunit is an enterprise-focused medical AI company specializing in cancer screening, medical imaging analysis, digital pathology, and precision oncology. Founded in South Korea in 2013, the company develops artificial intelligence software intended to help healthcare professionals detect cancer earlier, interpret medical images, assess biomarkers, and make more informed clinical decisions. Its technology is designed for hospitals, diagnostic imaging centres, pathology laboratories, research institutions, and pharmaceutical and biotechnology companies. Rather than offering a general-purpose AI assistant, Lunit concentrates on specialized medical applications that support different stages of cancer care, from screening and diagnosis to treatment research and drug development.

The company’s technology ecosystem is organized around two major product families: Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT focuses on medical imaging and cancer screening, while Lunit SCOPE provides AI-powered pathology and biomarker analysis for precision oncology. Together, these product families are intended to connect imaging-based detection with more detailed analysis of cancer tissue and potential treatment responses. Lunit also offers breast health and screening management solutions through its expanded product ecosystem, which includes technologies associated with Volpara.

Lunit INSIGHT is the company’s medical imaging platform. It uses AI models to analyse medical images and identify findings that may require a closer examination by a radiologist or other qualified healthcare professional. The platform is designed to work with existing clinical imaging workflows, helping medical teams process examinations, prioritize cases, and review potentially significant findings. Its products cover chest X-rays, conventional mammography, and digital breast tomosynthesis, giving healthcare organizations options for different screening and diagnostic requirements.

One of its key products is Lunit INSIGHT CXR, which analyses chest X-ray images for abnormalities associated with several thoracic conditions. The system is designed to identify suspicious findings and provide visual indicators that can help radiologists review examinations more efficiently. Its applications include supporting tuberculosis screening and identifying other chest abnormalities. Lunit also offers Lunit INSIGHT CXR Triage, which is designed to identify urgent findings and help prioritize examinations that may require faster clinical attention. These tools are intended to support professional interpretation rather than replace the judgment of a radiologist.

For breast imaging, Lunit provides Lunit INSIGHT MMG, an AI solution for analysing two-dimensional mammography examinations. It assists in identifying suspicious breast lesions and provides information that can support breast cancer screening and image interpretation. Another product, Lunit INSIGHT DBT, is designed for digital breast tomosynthesis, a three-dimensional breast imaging technique. It helps users review the multiple image slices produced during a DBT examination by highlighting areas that may deserve closer attention. These products are intended to support breast imaging teams by making image review more organized and helping them identify potentially important findings.

Lunit’s wider breast health ecosystem includes products and services that support screening quality, breast density assessment, patient management, and risk evaluation. Volpara Scorecard provides automated breast density assessment, while Volpara Live offers feedback intended to help imaging teams improve mammography positioning and image quality. Analytics provides performance monitoring and quality-related information for breast imaging facilities. Patient Hub supports patient communication and screening management, while Risk Pathways helps healthcare organizations identify and monitor people who may have an elevated risk of breast cancer. The company also presents image-based breast cancer risk estimation as part of its developing screening portfolio. Availability and regulatory status differ between products and markets, so healthcare organizations need to confirm which solutions are approved for their intended use.

The second major product family, Lunit SCOPE, focuses on digital pathology and precision oncology. It applies AI to tissue images and other pathology information to identify patterns and quantify biomarkers that may be relevant to cancer research and treatment development. The platform is particularly relevant to pharmaceutical companies, biotechnology organizations, pathology laboratories, and research teams investigating how patients may respond to different cancer therapies. By extracting measurable information from tissue samples, the technology can help researchers examine tumour characteristics and explore potential biomarkers for clinical studies.

Lunit SCOPE IO is designed to analyse tumour microenvironment characteristics using H&E-stained tissue images. It identifies tissue and cellular features that may be useful in research involving immuno-oncology therapies. This can help researchers investigate relationships between tumour characteristics and potential treatment responses. Lunit SCOPE also includes immunohistochemistry analysis solutions, including products for quantifying protein expression and patterns in tissue samples. These capabilities are relevant to biomarker research involving targeted therapies and antibody-drug conjugates.

The Lunit SCOPE IHC portfolio includes solutions such as Lunit SCOPE uIHC and Lunit SCOPE PD-L1, which support the analysis of immunohistochemical markers. Lunit SCOPE HER2 is another part of the company’s biomarker-related product offering. These tools are intended to provide quantitative information that researchers and laboratory teams can use when studying tumour tissue and treatment-related biomarkers. The platform also includes Lunit SCOPE GP, which is designed to predict selected genomic alterations from pathology images. This type of analysis can support research into biomarker discovery, patient selection, and clinical trial development. Importantly, Lunit states that Lunit SCOPE is for research use only and is not intended for use in diagnostic procedures. Its outputs should therefore not be presented as independently established clinical diagnoses.

Lunit’s technology is developed using large collections of medical images and pathology data. The company describes its models as being trained and evaluated using data from clinical partnerships and research collaborations. These datasets include chest X-rays, mammograms, digital breast tomosynthesis images, and digital pathology material such as H&E and IHC slides. The use of varied clinical data is intended to help the company develop models that can be applied across different healthcare environments. Lunit also invests in research and development to improve model performance and extend its capabilities across cancer screening and precision oncology.

Integration is an important part of Lunit’s product strategy. Medical imaging solutions are designed to work with hospital systems and established radiology workflows rather than requiring healthcare organizations to replace their entire imaging infrastructure. Lunit INSIGHT supports integration with Picture Archiving and Communication Systems and Radiology Information Systems, as well as standard DICOM-based imaging workflows. The company also works with medical imaging manufacturers and healthcare technology providers to distribute and integrate its products. Its partner ecosystem includes organizations such as GE HealthCare, Philips, Fujifilm, Hologic, Agfa HealthCare, and Sectra. These relationships help make its technology available through existing imaging equipment and clinical IT environments.

Lunit also works with pharmaceutical companies, biotechnology organizations, and laboratory partners in the precision oncology field. These collaborations can involve biomarker research, pathology analysis, companion diagnostic development, and clinical trial-related activities. Its partnerships and research agreements are intended to help connect AI-based tissue analysis with the development and evaluation of cancer treatments. This gives Lunit a role beyond radiology software, extending its technology into the research and development activities of the pharmaceutical industry.

The company’s commercial model is primarily business-to-business. Hospitals, imaging centres, medical device manufacturers, and other healthcare organizations can discuss product access and deployment requirements with Lunit. Depending on the solution, the commercial arrangement may involve a subscription, usage-based fees, integration with imaging equipment, or an agreement based on the volume of examinations processed. Some arrangements may also include maintenance and support services. This means that pricing can vary according to the selected product, number of imaging devices, examination volume, deployment method, and contractual requirements.

Lunit’s products are intended for professional healthcare environments, and regulatory status is an important consideration when selecting a solution. Certain Lunit INSIGHT products have received regulatory clearances or certifications in specific markets, including approvals from the United States Food and Drug Administration and certification under European medical device regulations. However, not every product or feature has the same regulatory status in every country. Healthcare providers should confirm local authorization, product availability, intended use, and integration requirements before implementation. Lunit’s AI systems are designed to assist qualified professionals, not to replace independent clinical judgment or the responsibility of medical practitioners.

The platform can be useful in several areas of healthcare. Radiology departments can use compatible INSIGHT products to support image review and examination prioritization. Breast imaging centres can use the company’s mammography and breast health solutions to support screening workflows, image quality monitoring, and risk management. Pathology laboratories and research teams can use SCOPE products to quantify tissue characteristics and investigate biomarkers. Pharmaceutical and biotechnology companies can explore these capabilities in research programmes and clinical development activities.

Lunit has developed a broad international presence through distribution agreements, research partnerships, and deployments across healthcare organizations. Its business combines medical AI research with commercial products intended for real clinical and laboratory workflows. This approach allows the company to serve both healthcare providers that need imaging support and life science organizations that require pathology-based insights for oncology research. Its focus on cancer care gives it a more specialized position than general medical software providers, although the value of each product depends on the clinical setting, available data, regulatory requirements, and the needs of the organization using it.

Lunit is best suited to organizations that already operate professional medical imaging, pathology, or oncology research workflows. It is not a consumer application for people who want to upload personal medical images and receive an independent diagnosis. Instead, it provides specialized tools for qualified healthcare professionals and research organizations. Its product range, imaging integrations, pathology analysis capabilities, and partnerships make it a relevant option for institutions seeking AI-assisted cancer screening and precision oncology technology.

Pricing

Lunit uses a business-to-business pricing structure, and its products do not have one publicly listed price that applies to every customer. Commercial arrangements vary by product and deployment model. Lunit INSIGHT may be offered through image-based usage fees, subscriptions billed monthly or quarterly, agreements involving imaging equipment, or annual SaaS contracts. Lunit SCOPE and other precision oncology solutions are generally discussed through research, laboratory, or enterprise partnerships. Interested organizations need to contact the company for a quotation based on their requirements.

Review

Lunit is a specialized medical AI platform with a strong focus on cancer screening and precision oncology. Its main advantage is the breadth of its product ecosystem, which covers chest X-ray analysis, mammography, digital breast tomosynthesis, breast screening management, digital pathology, and biomarker research. This gives hospitals and research organizations access to different AI-supported capabilities from one company rather than requiring them to evaluate every application separately.

The Lunit INSIGHT product family is particularly relevant to radiology departments. Its support for chest X-rays and breast imaging, combined with PACS and RIS compatibility, makes it suitable for organizations looking to introduce AI into established imaging workflows. The breast health products also extend its usefulness beyond image interpretation by supporting image quality monitoring, density assessment, and patient management.

Lunit SCOPE adds value for pathology and oncology research. Its tissue-image analysis and biomarker quantification capabilities can help research teams examine tumour characteristics and investigate treatment-related markers. The inclusion of different analysis approaches gives pharmaceutical and biotechnology organizations options for biomarker discovery and clinical development work.

However, Lunit is not a general-purpose healthcare application, and its products are not intended for ordinary consumers. Access is designed around professional healthcare and research environments. Implementation may require compatible imaging systems, technical integration, staff training, and commercial agreements. Pricing is not transparent to individual buyers, which can make it difficult for smaller organizations to estimate costs before contacting the company.

Regulatory and intended-use differences also need attention. A product cleared for a particular purpose in one country may not have the same authorization elsewhere. In addition, Lunit SCOPE is designated for research use and should not be confused with a clinically authorized diagnostic tool. Organizations must assess the status and intended use of each product before relying on it in their workflows.

Overall, Lunit is a strong option for hospitals, imaging centres, pathology laboratories, and life science organizations seeking specialized AI technology for cancer screening and oncology research. Its broad product range, established healthcare partnerships, and focus on clinical integration are notable strengths. Its enterprise-oriented pricing, technical implementation requirements, and product-specific regulatory limitations are important considerations for prospective customers.